Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 6:13:1-14.
doi: 10.2147/JIR.S229691. eCollection 2020.

Saturated Fatty Acids in Obesity-Associated Inflammation

Affiliations
Review

Saturated Fatty Acids in Obesity-Associated Inflammation

Heping Zhou et al. J Inflamm Res. .

Abstract

Obesity is a major risk factor for the development of various pathological conditions including insulin resistance, diabetes, cardiovascular diseases, and non-alcoholic fatty liver disease (NAFLD). Central to these conditions is obesity-associated chronic low-grade inflammation in many tissues including adipose, liver, muscle, kidney, pancreas, and brain. There is increasing evidence that saturated fatty acids (SFAs) increase the phosphorylation of MAPKs, enhance the activation of transcription factors such as nuclear factor (NF)-κB, and elevate the expression of inflammatory genes. This paper focuses on the mechanisms by which SFAs induce inflammation. SFAs may induce the expression inflammatory genes via different pathways including toll-like receptor (TLR), protein kinase C (PKC), reactive oxygen species (ROS), NOD-like receptors (NLRs), and endoplasmic reticulum (ER) stress. These findings suggest that SFAs act as an important link between obesity and inflammation.

Keywords: Toll-like receptor; inflammation; lipid rafts; obesity; protein kinase C; reactive oxygen species; saturated fatty acids.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
SFAs induce inflammation via several potential mechanisms.

References

    1. Pi-Sunyer X. The medical risks of obesity. Postgrad Med. 2009;121(6):21–33. doi:10.3810/pgm.2009.11.2074 - DOI - PMC - PubMed
    1. Unamuno X, Gomez-Ambrosi J, Rodriguez A, Becerril S, Fruhbeck G, Catalan V. Adipokine dysregulation and adipose tissue inflammation in human obesity. Eur J Clin Invest. 2018;48(9):e12997. doi:10.1111/eci.2018.48.issue-9 - DOI - PubMed
    1. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012;56(3):704–713. doi:10.1016/j.jhep.2011.09.020 - DOI - PMC - PubMed
    1. Wu H, Ballantyne CM. Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest. 2017;127(1):43–54. doi:10.1172/JCI88880 - DOI - PMC - PubMed
    1. Ramkumar N, Cheung AK, Pappas LM, Roberts WL, Beddhu S. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr. 2004;14(4):201–207. doi:10.1016/S1051-2276(04)00133-5 - DOI - PubMed